Skip to main content
OpenTrials
Completed

NCT Number: NCT03193879

Effects of Particulate Matter on the Pulmonary Function and Acute Exacerbation of COPD and Asthma

Particulate matter(PM) exposure has been shown to increase the morbidity and mobility of a variety of respiratory diseases, including COPD and asthma. This study focus on the effects of PM on the pulmonary function and acute exacerbation of COPD and asthma patients in China, where PM exposure is much heavier than the United States and European countries.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Particulate matter(PM) exposure has been shown to increase the morbidity and mobility of a variety of respiratory diseases, including COPD and asthma. This study focus on the effects of PM on the pulmonary function and acute exacerbation of COPD and asthma patients in China, where PM exposure is much heavier than the United States and European countries. This study is an observational study which lasts 3 years. Primary outcome measures:Change in spirometry (FEV1) of COPD, asthma patients and healthy volunteers in response to different exposure doses of PM.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • COPD patients: clinical manifestation of COPD; post bronchodilator FEV1/FVC<0.70.
  • Asthma patients: clinical manifestation of asthma; recurrent dyspnea; with or without wheezing; relief spontaneously or after using bronchodilators; FEV1/FVC<0.70,with positive bronchial reversible test.
  • Asthma combined with COPD (ACOS) patients: patients with ACOS are included in asthma group.
  • Healthy volunteers: No smoking history, or have quit smoking at least 5 years. Chest X-ray show no abnormality.
  • Information consent form should be signed before entering the study.

Exclusion criteria

  • The latest severe acute attack occurred within 4 weeks:
  • Severe acute attack: status asthmaticus or acute exacerbation of COPD leading to consultation, emergency treatment,hospitalization, or glucocorticoid treatment(oral/i.v).
  • Controllable non-hospitalized acute attack without glucocorticoid treatment(oral/i.v). COPD attack lasting less than 48h or asthma attack lasting less than 24h are not excluded.
  • Any history of acute/chronic respiratory diseases other than asthma and COPD, including lung cancer and pulmonary infection.
  • Plasma ALT or AST greater than 2 times of the upper normal limit; plasma Creatinine greater than 1.5 times of the upper normal limit.
  • Left heart insufficiency, or malignant arrhythmia.
  • HIV positive.
  • Acute cerebrovascular events within 3 months, including apoplexy, transient cerebral ischemia and acute coronary syndrome.
  • Uncured malignant tumors.
  • Addicted to drug or alcohol, or any history of psychiatric disorders.
  • Breastfeeding, pregnancy or planning to be pregnant.
  • Estimated lifetime less than 2 years due to underlying diseases.

Treatment and study plan

Primary outcomes

  1. Change in spirometry (FEV1) of COPD, asthma patients and healthy volunteers in response to different exposure doses of PM.

    Time frame: 2 years

    Spirometry will be assessed at baseline and through study completion, an average of 2 years.

Secondary outcomes

  1. Change in morbidity of acute exacerbation in COPD and asthma patients in response to different exposure doses of PM.

    Time frame: 2 years

    Patients will be followed up through study completion, an average of 2 years.

Sponsors and collaborators

Lead sponsor

Peking Union Medical College Hospital

Other

Collaborators

  • 3201 Hospital in Hanzhong
  • Beijing Boai Hospital
  • Beijing Fengtai Hospital
  • Cangzhou Central Hospital
  • Changzhi Medical College
  • Chengde Central Hospital
  • Chengdu Fifth People's Hospital
  • Chengdu sixth People 's Hospital
  • Chinese People 's Liberation Army Navy Anqing Hospital
  • Chongqing Jiangjin Central Hospital
  • First People 's Hospital of Changsha
  • First People 's Hospital of Kunming
  • Fujian Provincial Hospital
  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences
  • Guilin Medical University, China
  • Harbin Zhongshan Asthma Hospital
  • Jiangxi People 's Hospital
  • Northern Jiangsu People 's Hospital
  • Pingxiang People 's Hospital
  • Rizhao Hospital of Chinese Traditional Medicine
  • Second Hospital of Jilin University
  • Shanghai Zhongshan Hospital
  • ShuGuang Hospital
  • Sir Run Run Shaw Hospital
  • Taizhou Hospital
  • The Affiliated Hospital of Inner Mongolia Medical University
  • The Affiliated Hospital of Medical College, Ningbo University
  • The First Affiliated Hospital of the Fourth Military Medical University
  • The First People's Hospital of Jingzhou
  • The First People's Hospital of Yunnan
  • The Second Affiliated Hospital of Harbin Medical University
  • The Second Economic Hospital of Xinjiang Uygur Autonomous Region
  • Third Affiliated Hospital of Xinjiang Medical University
  • Wuhu County Traditional Chinese Medicine Hospital
  • Xiangya Hospital of Central South University
  • Xinjiang Autonomous Region People 's Hospital
  • Yancheng Dafeng People 's Hospital

Registry information

Official study title

Effects of Particulate Matter on the Lung Function and Acute Exacerbation of COPD and Asthma Patients--A Multi-center Cohort Study

Important dates

Study start
2015
Primary completion
2021
Study completion
2021
First posted
Jun 21, 2017
Registry last updated
Sep 21, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.